Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $24

Moomoo NewsDec 20 13:43 ET · Ratings

Stoke Therapeutics Initiated at Buy by Chardan Capital

Dow JonesDec 20 06:57 ET · Ratings

Stoke Therapeutics Price Target Announced at $24.00/Share by Chardan Capital

Dow JonesDec 20 06:57 ET · Ratings

Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth

Yahoo FinanceDec 17 06:39 ET

Stoke Therapeutics (NASDAQ:STOK) Pulls Back 9.1% This Week, but Still Delivers Shareholders Impressive 136% Return Over 1 Year

Simply Wall StDec 14 08:53 ET

Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 13,945 Shares

Quiver QuantitativeDec 10 19:16 ET